Does Skyrizi cause weight loss
Skyrizi (risankizumab) is a prescription medication for moderate to severe plaque psoriasis, active psoriatic arthritis, and Crohn disease. It works by targeting interleukin-23 (IL-23), which plays a key role in inflammatory pathways. Because IL-23 is involved in immune regulation and metabolic processes, people sometimes wonder whether Skyrizi causes weight loss as a treatment effect. In clinical trials, some individuals have experienced changes in body weight, but this is typically considered a secondary observation rather than a primary outcome. Weight changes can stem from reduced inflammation, improved symptom control, or other factors, and are not a guaranteed or intended result of therapy.
How Skyrizi works in the body
Skyrizi is a humanized monoclonal antibody that binds to interleukin-23, preventing it from interacting with its cell surface receptor. By blocking IL-23, Skyrizi helps calm overactive immune responses that drive inflammation in psoriasis, psoriatic arthritis, and Crohn disease. This mechanism can lead to improvements in skin clearance, joint symptoms, and gastrointestinal issues. However, while inflammation reduction may influence metabolism and body composition, Skyrizi is not studied or approved specifically for weight management.
Key targets of risankizumab
- Interleukin-23 (IL-23): The primary biologic target
- Inflammatory cytokines: Downstream signals reduced as a result
- Immune cells: Modified activity in pathways relevant to psoriasis and Crohn disease
What clinical trials show about weight
In pivotal trials for psoriasis, psoriatic arthritis, and Crohn disease, investigators tracked body weight among other safety and efficacy measures. Some participants report weight loss, but this is variable and influenced by diet, baseline disease activity, concomitant medications, and individual metabolism. Trials typically do not list weight loss as a primary endpoint, so the frequency and clinical significance of weight change are not precisely defined across all patients.
Reported outcomes in trials
| Attribute | Verified Detail | Source Type |
|---|---|---|
| Medication | Skyrizi (risankizumab) | Regulatory label |
| Approved indications | Plaque psoriasis, psoriatic arthritis, Crohn disease | Regulatory label |
| Weight loss as primary endpoint | No | Clinical trial protocols |
| Reported weight change | Variable; not consistent across all patients | Trial safety summaries |
| Typical monitoring | Weight may be recorded but is not a required efficacy measure | Clinical practice guidance |
Practical considerations for people on Skyrizi
If you are starting or continuing Skyrizi, focus on medically appropriate goals such as achieving clearer skin, improving joint function, and reducing gastrointestinal symptoms. Any changes in weight should be evaluated in context of overall health, nutrition, and activity level. Because inflammation can affect appetite and metabolism, some people notice gradual shifts in body weight after achieving better disease control. Discuss any concerns about weight with your healthcare provider, who can consider your full treatment picture.
Points to discuss with your clinician
- Baseline weight and body composition
- Changes over time during treatment
- Concomitant medications that may influence weight
- Diet, exercise, and lifestyle factors
- Safety monitoring and follow-up lab work
Safety and side effect profile
Common side effects of Skyrizi include injection site reactions, upper respiratory infections, and headache. Serious risks include infections, malignancies, and immune-related effects, as with other biologics. Weight loss alone is not typically flagged as a common side effect, but notable or unexplained changes should be reported to your clinician. Regular follow-up and monitoring support safe use regardless of minor weight fluctuations.
When to expect improvements
Some patients notice early improvements in symptoms within weeks, but meaningful changes in disease activity often build over several months. Because inflammation reduction can influence body composition and appetite, subtle weight shifts may coincide with clinical improvement. These changes are highly individual and are not the primary purpose of treatment.
Summary of current evidence
Skyrizi does not consistently cause weight loss, and weight change is not a defined treatment outcome. Some people experience weight loss, gain, or no change, influenced by disease activity, medications, lifestyle, and biology. The drug’s main role remains controlling inflammatory conditions for which it is approved. Any weight-related concerns should be discussed with your healthcare provider as part of an overall care plan.
